mcf-7/adr cells

γ-Tocotrienol (Plastochromanol) is one of the four types of tocotrienol, a type of vitamin E. Itl is also a radioprotector, antioxidant. It shows antitumor and antihypertensive effects in vivo.

T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic.

σ1 Receptor antagonist-1 is a selective σ1 receptor antagonist.

ABCB1-IN-2 (compound 16q) is a functional inhibitor that directly binds and stabilizes the ABCB1 protein structure without altering its expression and subcellular localization. This compound enhances the sensitivity of MCF-7/ADR cells to paclitaxel (PTX) by increasing PTX accumulation and inhibiting the ABCB1-mediated accumulation and excretion of luciferin Rh123. As a potent ABCB1-mediated multidrug resistance (MDR) reversal agent, ABCB1-IN-2 effectively reverses MDR.

P-gp inhibitor 28 (Compound 4h) is an inhibitor of P-glycoprotein (P-gp) that can suppress cancer cell proliferation, with an IC50 value ranging from 15.88 to 21.96 μM in MCF-7/ADR cells. This compound enhances the accumulation of Rho123 in MCF-7/ADR cells and is applicable for research in cancer treatment and overcoming tumor multidrug resistance.

P-gp inhibitor 20 (Compound H27) is a P-glycoprotein (P-gp) inhibitor characterized by low cytotoxicity. It reverses multidrug resistance (MDR) in MCF-7/ADR cells by inhibiting the efflux function of P-gp in a dose-dependent manner without affecting P-gp expression, with an IC50 value of 46.6 nM. P-gp inhibitor 20 is suitable for cancer research.

AKR1B1/STAT3/SLC7A11-regulator-1 (5a) is a modulator of the AKR1B1/STAT3/SLC7A11 pathway, capable of reversing DOX resistance in MCF-7/ADR cells by enhancing ferroptosis (apoptosis) activity. It is utilized in breast cancer research.

PB28 dihydrochloride is a selective and potent sigma 2 (σ2) receptor agonist and σ1 receptor antagonist with anti-SARS-CoV-2 activity and anti-tumor activity, which inhibits cell proliferation and invasion and suppresses SKF by modulating the PI3K-AKT-mTOR signaling pathway in renal cancer. It inhibits cell proliferation and invasion by regulating the PI3K-AKT-mTOR signaling pathway in renal cancer, inhibits calcium release from the endoplasmic reticulum of SK-N-SH neuroblastoma cells, and induces non-caspase-dependent apoptosis.

(S)-α-Methylbenzyl ricinoleamide is a fatty acid amide derived from ricinoleic acid and methyl benzylamine. It demonstrates potent growth inhibition of glioma (U251), breast (MCF-7), ovarian (NCI-ADR/RES and OVCAR-3), kidney (786-0), non-small cell lung (NCI-H460), and prostate (PC-3) cancer cells with a mean GI50 value of 6.9 μM.

C4 Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. [1] [2] [3] It inhibits IL-4 production by 16% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. [1] C4 Ceramide is cytotoxic to SK-BR-3 and MCF-7/Adr breast cancer cells (IC50s = 15.9 and 19.9 μM, respectively). [2] C4 Ceramide also increases maturation and stability of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation, enhances cAMP-activated chloride secretion, and suppresses secretion of IL-8 in primary epithelial cells isolated from patients with cystic fibrosis.[3]

P-gb-IN-1 is a potent P-glycoprotein (P-gp) inhibitor that exhibits reverse activity by inhibiting P-gp outflow. P-gb-IN-1 has been shown to inhibit P-gp by hydrogen bonding with residues Asn 721 and Met 986. P-gb-IN-1 showed low toxicity in MCF-7/ADR cells.

P-gp Inhibitor 22 effectively inhibits P-glycoprotein (P-gp) and its efflux function, promoting apoptosis and the accumulation of MCF-7/ADR cells in the S phase [1].